Anika Therapeutics, Inc.
ANIK
$9.35
$0.303.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.53% | -- | -- | -33,897.73% | 98.05% |
| Total Depreciation and Amortization | -11.06% | -- | -- | 6.32% | -0.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.23% | -- | -- | 524.71% | -23.08% |
| Change in Net Operating Assets | -1,324.91% | -- | -- | 118.55% | -92.44% |
| Cash from Operations | -45.38% | -- | -- | 569.22% | -748.41% |
| Capital Expenditure | 48.05% | -- | -- | 64.27% | -88.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -179.36% | -- | -- | -- | -- |
| Cash from Investing | -132.24% | -- | -- | 46.64% | -88.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 1,917.39% |
| Repurchase of Common Stock | 98.49% | -- | -- | -153.40% | 31.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.29% | -- | -- | -259.23% | 51.12% |
| Foreign Exchange rate Adjustments | 219.44% | -- | -- | 250.45% | -622.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.61% | -- | -- | 92.18% | -37.02% |